EMP2 antibodies and methods of use thereof for causing regression of a solid tumor or symptoms thereof
The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.
1. An isolated antibody that competes for binding to the extracellular loop of a human Epithelial Membrane Protein2 (EMP2) (SEQ ID NO:42) with an EMP2 inhibitor, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises three heavy chain complementary determining regions (HCDRs) and wherein the light chain variable region comprises three light chain variable regions (LCDRs), wherein:
the sequence of HCDR1 is SEQ ID NO:14,
the sequence of HCDR2 is SEQ ID NO:16,
the sequence of HCDR3 is SEQ ID NO:37,
the sequence of LCDR1 is SEQ ID NO:19,
the sequence of LCDR2 is SEQ ID NO:22, and
the sequence of LCDR3 is SEQ ID NO:38.
2. The antibody of claim 1 , wherein the antibody is a monoclonal antibody, a humanized monoclonal antibody, a human antibody, a diabody, minibody, or triabody, a chimeric antibody, or a recombinant antibody.
3. The antibody of claim 1 , wherein the antibody is in scFv, minibody, diabody, or triabody format.
4. The antibody of claim 1 , wherein the antibody is conjugated to a cytotoxic agent or a label.
5. A pharmaceutical composition comprising the antibody of claim 1 and a physiologically acceptable carrier.
6. A method for causing regression of a solid tumor or symptoms thereof in a subject the method comprising the administration of an effective amount of an antibody that binds to Epithelial Membrane Protein2 (EMP2) wherein the antibody comprises the three HCDRs and the three LCDRs of the antibody of claim 1 .
7. The method of claim 6 , wherein the cancer is selected from the group consisting of ovarian cancer, glioblastoma, breast cancer, prostate cancer, testicular cancer and myeloma.
8. The method of claim 6 , wherein the cancer is endometrial cancer.
9. An isolated antibody which binds to Epithelial Membrane Protein 2 (EMP2), wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises three heavy chain complementary determining regions (HCDRs) and wherein the light chain variable region comprises three light chain variable regions (LCDRs), wherein:
the sequence of HCDR1 is SEQ ID NO:14,
the sequence of HCDR2 is SEQ ID NO:16,
the sequence of HCDR3 is SEQ ID NO:37,
the sequence of LCDR1 is SEQ ID NO:19,
the sequence of LCDR2 is SEQ ID NO:22, and
the sequence of LCDR3 is SEQ ID NO:38.
10. The antibody of claim 9 , wherein the antibody is a monoclonal antibody, a humanized monoclonal antibody, a human antibody, a diabody, minibody, or triabody, a chimeric antibody, or a recombinant antibody.
11. The antibody of claim 9 , wherein the antibody is in scFv, minibody, diabody, or triabody format.
12. The antibody of claim 9 , wherein the antibody is conjugated to a cytotoxic agent or a label.
13. A pharmaceutical composition comprising the antibody of claim 9 and a physiologically acceptable carrier.
14. A method for causing regression of a solid tumor or symptoms thereof in a subject the method comprising the administration of an effective amount of an antibody that binds to Epithelial Membrane Protein 2 (EMP2) wherein the antibody comprises the three HCDRs and the three LCDRs of the antibody of claim 9 .
15. The method of claim 14 , wherein the cancer is selected from the group consisting of ovarian cancer, glioblastoma, breast cancer, prostate cancer, testicular cancer and myeloma.
16. The method of claim 1 , wherein the cancer is endometrial cancer.